21/11/2017 13:30:21

Metso Corporation: Managers' transactions - Nico Delvaux

Related content
18 Jun - 
Metso receives major valve orders for more than 8,000 v..
21 May - 
Pekka Vauramo appointed President and CEO of Metso Corp..
30 Apr - 
Metso Corporation: Managers' transactions - Peter Carls..

Metso Corporation: Managers' transactions - Nico Delvaux

Metso Corporation's stock exchange release, November 21, 2017 at 3:30 p.m. EEST

Metso Corporation has received the following disclosure under EU Market Abuse Regulation No 596/2014, regarding managers' or their closely associated persons' transactions with Metso's shares.

Person subject to the notification requirement

Name:

Delvaux, Nico 

Position:

Chief Executive Officer
   

Initial Notification

 

Reference number:

2138007FRMWVPUDCMA45_20171120151628_15
   

Issuer

Name:

Metso Corporation

LEI:

2138007FRMWVPUDCMA45
   

Transaction details

Transaction date:

2017-11-20+02:00

Venue:

NASDAQ HELSINKI LTD (XHEL)

Nature of the transaction:

Acquisition
 

Instrument:

Share
 

Volume:

1300

Unit price:

29.50 Euro
 

Aggregated transactions

Volume:

1300

Volume weighted average price:

29.50 Euro

Metso is a world leading industrial company serving the mining, aggregates, recycling, oil, gas, pulp, paper and process industries. We help our customers improve their operational efficiency, reduce risks and increase profitability by using our unique knowledge, experienced people and innovative solutions to build new, sustainable ways of growing together.

Our products range from mining and aggregates processing equipment and systems to industrial valves and controls. Our customers are supported by a broad scope of services and a global network of over 80 service centers and about 6,000 services professionals. Metso has an uncompromising attitude towards safety.

Metso is listed on the Nasdaq Helsinki in Finland, and had sales of about EUR 2.6 billion in 2016. Metso employs over 11,000 people in more than 50 countries. Expect results. 

metso.com, twitter.com/metsogroup     

Further information, please contact:

Juha Rouhiainen, VP, Investor Relations, Metso Corporation, tel +358 20 484 3253

 

Metso Corporation

Eeva Sipilä

CFO

Juha Rouhiainen

VP, Investor Relations

Distribution:

NASDAQ OMX Helsinki Ltd

Media

www.metso.com


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Metso Corporation via Globenewswire

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
Ingen indlæg

HSBC Bank Plc : Form 8.5 (EPT/RI) - Lonmin PLC

22/02/2018 10:54:53
FORM 8.5 EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Name of exempt principal trader: HSBC BANK PLC (b) Name of offeror/offeree i..

Rathbone Brothers Plc : Preliminary announcement of 2017 results

22/02/2018 07:00:19
Funds under management up 14.3% to £39.1 billionThis is a preliminary statement of annual results published in accordance with FCA Listing Rule 9.7A. It covers the year ended 31 December 2017. Mark Nicholls, Chairman of Rathbone Brothers Plc, said: "UK and global investment markets performed well in 2017, with some indices reaching record levels towards the end of the year. This outcome has b..

Elliott Capital Advisors, L.P : Form 8.3 - GKN Plc

Related news
21/02/2018 15:25:10
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Elliott Capital Advisors, L.P. (for itself and related general partners ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Lexicon Pharmaceuticals Announces Positive 52-Week Results From Sotagliflozin inTandem2 Study Presented at ADA 2018 and Published in Diabetes Care
2
BIOLIFE4D Modifies its Regulation A+ (Mini-IPO) Offering Due to Popular Demand
3
Zealand Pharma presents two dasiglucagon milestone studies at the 78th Scientific Sessions of the American Diabetes Association (ADA)
4
Zafgen Announces Positive Full Results in Phase 2 Proof-of-Concept Trial of ZGN-1061 in Patients with Difficult-to-Control Type 2 Diabetes
5
Zealand Pharma presents two dasiglucagon milestone studies at the 78th Scientific Sessions of the American Diabetes Association (ADA)

Related stock quotes

Metso Corporation 28.78 -1.0% Stock price decreasing

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2018   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
24 June 2018 06:08:04
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20180619.1 - EUROWEB3 - 2018-06-24 07:08:04 - 2018-06-24 06:08:04 - 1000 - Website: OKAY